July 24, 2012 — Navidea Biopharmaceuticals Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced that clinical data from a head-to head study comparing its amyloid imaging candidate, AZD4694, to the benchmark amyloid imaging agent, 11C-PiB (PiB), was presented at the Alzheimer's Association International Conference (AAIC) in Vancouver, Canada by Professor Christopher Rowe, MD, FRACP, Director of the Department of Nuclear Medicine and Centre for PET at Austin Health, Melbourne, Australia.

July 23, 2012 — A recent study published in the American Journal of Roentgenology has reconfirmed that virtual colonoscopy (CT colonography) is an effective screening tool for colorectal cancer in seniors age 65 and older.

July 23, 2012 — Accuray Inc. announced it has signed a definitive agreement to acquire Morphormics Inc., a privately held company founded by University of North Carolina at Chapel Hill faculty members based on their research in autosegmentation of medical images.

July 23, 2012 — Viatronix Incorp. announced that the stage finally appears set for a reversal of the May 2009 non-coverage decision for screening CT Colongraphy (CTC) by The Centers for Medicare and Medicaid Services (CMS). The latest CTC study, "CT Colonography of a Medicare-Aged Population: Outcomes Observed in an Analysis of More Than 1,400 Patients" (American Journal of Roentgenology, AJR2012; 199:W27-W34), provides good evidence that CT Colonography is an effective screening tool for colorectal cancer in the Medicare-aged population. The lack of Medicare-age specific data on CTC was the primary reason given for CMS' non-coverage decision.

July 20, 2012 —Acusphere Inc. announced that it had completed the marketing authorization application (MAA) dossier for its lead product candidate, Imagify (perflubutane polymer microspheres) for injectable suspension, and is now starting the process of filing the MAA dossier with the European Medicines Agency (EMA) to support the regulatory review of Imagify in the European Union.

July 20, 2012 — On July 6, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule that would revise several reimbursement payment policies and rates for services furnished under the Medicare Physician Fee Schedule (MPFS) as of January 1, 2013. The proposed changes reflect an overall 15 percent reduction in payment for radiation oncology services, equaling a $300 million loss for the provision of cancer care services, according to the American Society for Radiation Oncology (ASTRO).